A more recent study confirmed an association between higher hypoxia scores with advanced prostate cancer; in contrast, PSA pretreatment levels do not correlate with hypoxia, as well with the most recurrent somatic mutational alterations [238]. This evidence concerns the gene PSAT1 and Familial prostate cancer.